41 results about "In vitro stimulation" patented technology

The invention belongs to the technical field of biology, and particularly relates to screening and identification of antigen epitope polypeptides. The invention discloses screening, identification and application of a series of rabies virus glycoprotein and nucleoprotein antigen epitope polypeptides. The rabies virus glycoprotein and nucleoprotein are predicted by biological information means to obtain the candidate epitope polypeptides; and a lymphopoiesis experiment, ELISPOT experiment and a stream-type cell method are utilized to carry out in-vitro experimental verification on the subsequent epitope polypeptides to obtain the four rabies virus protein antigen epitope polypeptides. The invention is characterized in that the antigen epitope polypeptides respectively comprise a Th epitope and a CTL epitope, can stimulate the lymphopoiesis of the vaccine-immunized mouse in vitro and induce the cells to secrete related cell factors, and have the functions of killing virus-infected cells and stimulating the generation of the antibody. The invention can be used for developing rabies virus epitope vaccines and detecting the vaccine effect, and has important value for developing and producing immunologic function detection kits for rabies virus vaccines.

The invention discloses an in-vitro test stimulator, and belongs to the technical field of implanted medical instruments. The in-vitro test stimulator is mainly used for nervous electric stimulation therapy test. The double-channel pulse output in-vitro test stimulator with a user interface can output accurate parameter adjustable electrical stimulation pulse, and is used for treatment test or short-term electric stimulation therapy experience of patients in implanted nerve stimulator operation. The test stimulator is characterized in that the test stimulator adopts integrated structural design, and mainly comprises a shell, a toggle switch, a film key, a display screen, a battery, a printed circuit board and the like. The test stimulator is small and simple; through the key and the switch, pulse parameters and test electrode load impedance can be adjusted and the polarity of an electrode contact can be set, so the test stimulator is intuitive and convenient to operate; and through the design of self-locking function and error operation prevention, error operation of the patients in use can be effectively prevented, and the test stimulator is safe and reliable. The test stimulator can be widely applied to test assessment and experience of electric stimulation therapy.

The invention provides a stimulation device of time-phase characteristics of coronary artery blood flow, which relates to the technical field of in vitro stimulation experiments and aims at solving the technical problems that the existing hemodynamic parameters of clinical patients and experimental animals have randomness and the blood flow is difficult to be measured. The device comprises a fluid line system which consists of a cardiac pump, an accumulator, a fluid flow loop and a fluid storage tank which are sequentially and circularly connected, and a motor which drives the cardiac pump to move; and the device is characterized in that: the fluid flow loop comprises a two- position three-way valve, a diastolic branch and a systolic branch; one end of the diastolic branch and the systolic branch is respectively connected with two outlets of the two-position three-way valve, and the other end is connected with the fluid storage tank, a common inlet of the two-position three-way valve is connected with the accumulator, and the two-position three-way valve is driven by the motor to cause the common inlet to be communicated with the diastolic branch and the systolic branch along with the alternation of the diastole and the systole of the cardiac pump, and fluid resistance of the systolic branch is greater than that of the diastolic branch. By adopting the stimulation device of the invention, the time-phase characteristics of the coronary artery blood flow can be reproduced.

The invention relates to a cells separating technology, and provides a tumor infiltrating lymphocytes separation method. The method is characterized by adding tumor tissue masses in a trypsin-EDTA solution for immersion and incubation, fully digesting and dispersing the tumor tissue masses; separating and collecting single cell and being resuspended by the trypsin-EDTA solution for multitime density gradient centrifugation, incubating and separating by an erythrocyte lysate, using calf serum-containing PBS buffer or resuspending to obtain the dissolved tumor infiltrating lymphocytes. In the invention, an enzymatic digestion method and a machinery method are combined for dual separating the enzymatic digestion with high efficiency, compared with the machinery method or the enzymatic digestion method, the survival rate of the obtained tumor infiltrating lymphocytes is high, and the method is simple and easy to operate. The obtained tumor infiltrating lymphocytes can be massively propagated through in vitro stimulation of interleukin 2 (1L-2), have antineoplastic activity with specialty and high efficiency, and provides powerful basis and new approach for treating tumour.

The present invention relates to the field of therapeutic immunization, specifically with the use of a novel hepatitis B virus (HBV) antigen formulation for cell stimulation. The formulation is formed by HBV surface antigen (HBsAg) and nucleocapsid antigen (HBcAg) precipitates in suspension. The formulation contains said antigens as precipitates in suspension as particles with sizes less than 500 nm and greater than 500 nm, in a mixture in which the proportion between the particles of the sizes mentioned is between 50% - 50% and 80% - 20%, respectively. The selection of a range of particle sizes allows the levels of stimulation of various cell types to be maximized. In addition, a description is given of a method for cell stimulation using said formulation and the subsequent passive immunization of patients with chronic hepatitis B, based on the maximum in vivo or in vitro stimulation of heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients with a chronic HBV infection.

The invention discloses a tumor composite antigen, a dendritic cell multivalent vaccine and application of the tumor composite antigen and the dendritic cell multivalent vaccine. Dendritic cells of a patient are stimulated in vitro, multiple tumor cell lysates with super immunogenicity aiming at different EBV related tumors are loaded, mature dendritic cells are formed under induction of multiple cell factors and specific agonists, a complete DC vaccine with corresponding cancer antigens is formed, the DC vaccine is transfused back to a human body to activate an immune system, and the EBV related tumors are subjected to tumor immunogenicity. Natural immunity (such as induction of NK cells) is stimulated, lymphocytes are stimulated to generate acquired immune response, cytotoxic T cells are generated to kill cancer cells, and the cancer cells are accurately killed together; compared with radiotherapy and chemotherapy, the composition is particularly safe and almost has no side effect; and the dendritic cell vaccine has a preparation cycle of about 1 week, and is short in time and low in cost.

The invention relates to the field of immune medicine, in particular to a rhamnose lactobacillus Pr2 peptide and a coding gene, a separation method and application thereof. The rhamnose lactobacillus Pr2 peptide has an amino acid sequence shown as SEQ No.1. The rhamnose lactobacillus sourced Pr2 peptide has the capability of producing Tregs through in-vitro stimulus. In addition, the Tregs can produce antigenic specificity Tregs when being exposed under Pr2 and antigen. The antigenic specificity Tregs can be activated when being exposed under specificity antigen. The activated antigenic specificity Tregs can release functional molecules such as IL-10, TGF- beta and FasL. The adoptive transfer of the antigenic specificity Tregs to a sensitized mouse or the giving of the Pr2 and specificityantigen to the sensitized mouse can obviously inhibit the antigenic specificity Th2 reaction and anaphylactic reaction in the body of the mouse. Therefore, the method has the potential application value in the treatment of food allergy diseases.

The invention provides compositions and methods for promoting stem cell and / or progenitor cell proliferation and / or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treatinga lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and / or treating injury to GI mucosa in a subject in need thereof. The invention also provides methods for promoting the proliferation and / or differentiation of stem cells and / or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and / or differentiation of stem cells and / or the progenitor cells in vivo, ex vivo and / or in vitro provides tremendous benefit. The compositions can be used to increase stem cell populations in vivo, ex vivo and / or in vitro. Stem cell transplantation provides treatments and / or cures of many disease states, degeneration and / or injury.

The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.

A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g / ml, and at least 1% of which are CD34+CD45− / dim, to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g / ml to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor / precursor cell population (PCP). Other embodiments are also described.

The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro; c) is capable of modulating tumor necrosis factor production; d) contains no measurable IL-1a, IL-1b, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-gamma; e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; f) shows no cytotoxicity to human peripheral blood mononuclear cells; and g) is not an endotoxin. The invention also relates to a method of preparing the composition and its use an immunomodulator.

The invention discloses an EBV (Epstein-Barr Virus) composite antigen, a dendritic cell vaccine and application of the dendritic cell vaccine in preparation of medicines for treating EBV-related infectious diseases, and belongs to the technical field of biological medicines. According to the invention, dendritic cells of a patient are stimulated in vitro, lysates of a plurality of EBV infected cells with superstrong immunogenicity for EBV-related infectious diseases are loaded, and the lysates are induced to mature under the conditions of a plurality of cytokines and specific agonists, so that a complete dendritic cell vaccine with corresponding antigens is formed; after being transfused back to a human body to activate an immune system, cytotoxic T cells are generated, EBV infected cells are killed, an immunological effect is exerted, and the life quality of a patient is improved; the dendritic cell vaccine has a preparation cycle of about 1 week, is short in time, low in cost, safe and almost free of side effects.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex(MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to the prevention and treatment of disease like cancer. The inventors have previously characterized MELOE-1 antigen as an IRES dependent, melanoma specific translation product from a lncRNA mainly transcribed in the melanocytic lineage. MELOE-1 contains numerous class II epitopes and one HLA-A*0201-restricted CD8 epitope eliciting a frequent repertoire of high avidity T cells. They designed various synthetic long peptide (SLPs) comprising a CD4 epitope coupled to the CD8 epitope by a serie of linkers of 4 to 6 aa and studied the efficacy of T cell clone activation by SLP-loaded DC in vitro. Particularly, they evaluated the ability of a few selected SLPs to stimulate specific T cells proliferation of PBL from healthy donors in vitro and finally, they explored the vaccination potential of their best SLP candidate in vivo in an HLA*A0201 / HLA-DRB0101 transgenic mouse. Thus, the present invention relates a SLP comprising a CD4 class II peptide linked to a CD8 class I peptide by a specific linker and its use in the treatment of disease like cancers.

The invention relates to a medical suture friction testing apparatus. The apparatus comprises an assembly for testing the friction performance of a medical suture when the medical suture penetrates tissues, and an assembly for testing the friction performance between medical sutures. The assembly for testing the friction performance of a medical suture penetrating tissues stimulates the friction performance between the medical suture and all tissues when the medical suture penetrates human tissues, and the assembly for testing the friction performance between medical sutures stimulates the friction assembly between the medical sutures in the knotting process of the medical suture. The two assemblies can be arranged in a multifunctional fiber strength and elongation tester to replace a lower clamping head of the tester in order to carry out relevant friction performance test. The invention also discloses a corresponding medical suture friction testing method. The friction testing apparatus has the advantages of simple structure, convenient operation, and objective and real result. The apparatus and the method fill up a blank in the quantitative characterization of present in-vitro stimulation of the friction performance of the medical suture, and provide scientific bases for the improvement of the structure of the medical suture.

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.

An apparatus and method for oocyte rescue in vitro post stimulation, the apparatus including a computing device, wherein the computing device includes at least a processor; and a memory communicatively connected to the at least processor, the memory containing instructions configuring the at least processor to: receive biological sample data from a biological sample relating to a user, including at least an oocyte; determine a maturity level of the at least an oocyte; assign the at least an oocyte to a culture protocol as a function of the maturity level; receive culture data relating to the at least an oocyte as a function of the culture protocol; and calculate a scoring metric as a function of the culture data.